Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Australia’s top drug regulator has issued a fresh safety warning about the potential risk of suicidal thoughts and ...

The Therapeutic Goods Administration issued a new warning for GLP-1 receptor agonists, including Ozempic and Mounjaro, on ...

WHO issues 1st guideline on GLP-1s recommending long-term use with behavioral therapy and notes pricing changes from major manufacturers.

The WHO’s announcement came hours after Australia released a safety alert over the potential risk of suicidal thoughts and behaviours for people using the medicines.

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

The World Health Organization has issued its first-ever guidelines for the use of GLP-1 drugs to treat obesity. The WHO has classified obesity as a chronic disease and endorsed the use of these drugs ...

Women who used a GLP-1 prior to pregnancy and stopped therapy 1 to 2 years before delivery had increased risk for preeclampsia, but reduced risk for developing gestational diabetes, according to study ...

Australia’s medicines regulator has issued a safety warning over the risk of suicidal thoughts and behaviour linked to drugs ...